Rocket Pharmaceuticals Inc.

03/29/2021 | Press release | Distributed by Public on 03/29/2021 05:02

Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I